Gsa Capital Partners LLP Spectrum Pharmaceuticals Inc Transaction History

Gsa Capital Partners LLP

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.32 - $0.52 $184,926 - $300,505	-577,895 Reduced 90.64%	59,677 $22,000
Q3 2022 Nov 14, 2022	BUY	$0.43 - $1.56 $274,155 - $994,612	637,572 New	637,572 $274,000
Q1 2022 May 11, 2022	SELL	$0.63 - $1.59 $258,735 - $652,998	-410,691 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$1.27 - $2.42 $409,249 - $779,830	-322,244 Reduced 43.97%	410,691 $522,000
Q3 2021 Nov 12, 2021	BUY	$2.15 - $3.82 $601,550 - $1.07 Million	279,791 Added 61.74%	732,935 $1.6 Million
Q2 2021 Aug 05, 2021	BUY	$2.89 - $4.45 $626,170 - $964,172	216,668 Added 91.62%	453,144 $1.7 Million
Q1 2021 May 10, 2021	BUY	$2.9 - $4.09 $249,115 - $351,339	85,902 Added 57.05%	236,476 $771,000
Q4 2020 Feb 03, 2021	BUY	$3.38 - $5.14 $508,940 - $773,950	150,574 New	150,574 $513,000
Q1 2020 May 12, 2020	SELL	$1.83 - $3.45 $42,721 - $80,540	-23,345 Closed	0 $0
Q4 2019 Feb 12, 2020	BUY	$3.5 - $10.35 $81,707 - $241,620	23,345 New	23,345 $85,000
Q3 2018 Nov 13, 2018	SELL	$16.52 - $24.82 $181,340 - $272,449	-10,977 Closed	0 $0
Q2 2018 Aug 09, 2018	SELL	$14.31 - $21.75 $85,860 - $130,500	-6,000 Reduced 35.34%	10,977 $230,000
Q1 2018 May 11, 2018	BUY	$16.09 - $23.07 $273,159 - $391,659	16,977 New	16,977 $273,000

115K

Ticker SPPI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,164,000
Description
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor ...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.